Biotech Spotlight
This startup thinks humans in clinical trials could become a ‘formality’
Deep Origin aims to use molecular physics and artificial intelligence to build predictive models that improve the success rate of drug development. Its long-term goal is to create a complete 'virtual human,' enabling computer-simulated trials to replace parts of real clinical trials. The company has received a $31.7 million contract from ARPA-H and plans to launch its first organ models by early next year.
Galimedix is keeping the amyloid hypothesis alive
Galimedix Therapeutics is continuing to bet on the therapeutic potential of the amyloid hypothesis in Alzheimer's disease and other ophthalmic conditions with new modalities and earlier intervention strategies. Its candidate drug GAL-101 aims to target misfolded monomers, blocking the toxic cascade at its source, and potentially avoiding the ARIA risks associated with existing antibody drugs. The company plans to release Phase II data for dry AMD in 2028, using more precise retinal function measurements to validate its technological approach.
Backed by Sanofi and Roche, Orano Med chases radiopharma leadership
Orano Med is leveraging the unique resources of its parent company Orano in the nuclear fuel cycle to extract lead-212 at scale and advance targeted alpha therapy. The company has established collaborations with Sanofi and Roche, and its core asset AlphaMedix has shown positive Phase II data. CEO Frederic Desdouits stated that the company possesses a complete value chain from isotope extraction to drug production, with the goal of becoming a global leader in radiopharmaceuticals.
A biotech’s snakebite pill is drawing the US military’s interest
California biotech company Ophirex is developing varespladib, the first oral emergency drug for snake bites, with funding primarily from the U.S. Department of Defense. The drug has received FDA's Animal Rule approval pathway, aiming to submit a New Drug Application by 2027.
Imunon’s non-viral DNA candidate may have cracked the code in frontline ovarian cancer
Imunon's non-viral DNA candidate IMNN-001, which provides the body with a 'recipe' to produce IL-12, demonstrated a 13-month improvement in overall survival in a Phase III trial, potentially reshaping the landscape of first-line ovarian cancer treatment.
CRISPR’s cardio catch-all drives a biotech’s broad potential
Scribe Therapeutics is a preclinical-stage biotechnology company co-founded by CRISPR pioneer Jennifer Doudna, dedicated to using the CRISPR platform to develop one-time gene medicines for the prevention of cardiometabolic diseases. Its X-Editor and ELXR platforms can be used synergistically or independently, aiming to enhance the safety and reversibility of gene editing. The company is advancing its lead candidate, STX1150, toward the clinic to lower low-density lipoprotein cholesterol levels, and has established partnerships with pharmaceutical companies such as Sanofi and Eli Lilly.
A biotech dousing ‘fires’ in the brain that plagued a bestselling author
Arialys Therapeutics is a preclinical-stage biotechnology company focused on developing treatments for anti-NMDA receptor encephalitis (ANRE), a rare and potentially fatal autoimmune disease. The company's lead candidate, ART5803, works by blocking pathogenic autoantibodies rather than suppressing the entire immune system. ANRE, known from the bestselling memoir 'Brain on Fire', is often misdiagnosed because it presents with psychiatric symptoms.
Emerging biotech company Ensho Therapeutics enters the oral α4β7 inhibitor arena, competing with Lilly and Gilead
Ensho Therapeutics is a newly established biotech company focused on developing oral α4β7 integrin inhibitors for the treatment of inflammatory bowel disease (IBD). The company officially launched at the end of June, has obtained a relevant asset portfolio from EA Pharma, and plans to initiate Phase 2a and Phase 2b studies for ulcerative colitis in 2025. This arena is highly competitive, with Lilly and Gilead also advancing clinical development of similar oral drugs.